Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.
Favaretto A, Paccagnella A, Tomio L, Sartori F, Cipriani A, Zuin R, Reffosco L, Calabro F, Rea F, Ghiotto C, Chiarion-Sileni V, Oniga F, Loreggian L, Fiorentino MV. Favaretto A, et al. Among authors: calabro f. Eur J Cancer. 1996 Nov;32A(12):2064-9. doi: 10.1016/s0959-8049(96)00248-1. Eur J Cancer. 1996. PMID: 9014746 Clinical Trial.
A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis.
Santo A, Pedersini R, Pasini F, Terzi A, Pari F, Cartei G, Sibau A, Molino A, Maiorino A, Panza N, Oletti MV, Maluta S, Calabrò F, Cetto GL. Santo A, et al. Among authors: calabro f. Lung Cancer. 2001 Dec;34 Suppl 4:S15-20. doi: 10.1016/s0169-5002(01)00400-7. Lung Cancer. 2001. PMID: 11742697 Clinical Trial.
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
Sternberg CN, Dumez H, Van Poppel H, Skoneczna I, Sella A, Daugaard G, Gil T, Graham J, Carpentier P, Calabro F, Collette L, Lacombe D; EORTC Genitourinary Tract Cancer Group. Sternberg CN, et al. Among authors: calabro f. Ann Oncol. 2009 Jul;20(7):1264-9. doi: 10.1093/annonc/mdn784. Epub 2009 Mar 17. Ann Oncol. 2009. PMID: 19297314 Free article. Clinical Trial.
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Sternberg CN, Calabrò F, Bracarda S, Cartenì G, Lo Re G, Ruggeri EM, Basso U, Gasparini G, Ciuffreda L, Ferrari V, Bonetti A, Fea E, Gasparro D, Tassinari D, Labianca R, Masini C, Fly K, Zhang K, Hariharan S, Capaccetti B, Porta C. Sternberg CN, et al. Among authors: calabro f. Oncology. 2015;88(5):273-80. doi: 10.1159/000369256. Epub 2015 Jan 15. Oncology. 2015. PMID: 25592399 Clinical Trial.
Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
Sonpavde GP, Sternberg CN, Loriot Y, Marabelle A, Lee JL, Fléchon A, Roubaud G, Pouessel D, Zagonel V, Calabro F, Banna GL, Shin SJ, Vera-Badillo FE, Powles T, Hellmis E, Miranda PAP, Lima AR, Emeribe U, Oh SM, Hotte SJ. Sonpavde GP, et al. Among authors: calabro f. Eur J Cancer. 2022 Mar;163:55-65. doi: 10.1016/j.ejca.2021.12.012. Epub 2022 Jan 15. Eur J Cancer. 2022. PMID: 35042068 Free article. Clinical Trial.
299 results